The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naive Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double- Blind Phase 3b Trial Article

sustainable development goals

publication date

  • July 1, 2017

webpage

published in

keywords

  • botulinum toxins
  • cholinergic antagonists
  • onabotulinumtoxinA
  • urinary bladder, overactive
  • urinary incontinence

start page

  • 167

end page

  • 175

volume

  • 198

issue

  • 1